Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins

Atopic dermatitis (AD) is the most common inflammatory skin disease in children, with 30% of all those diagnosed developing chronic or relapsing disease by adolescence. Such disease persistence cannot yet be predicted. The aim of the present study was to predict the natural course of AD using clinical parameters and serum proteins.

[1]  T. Nomura,et al.  Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity. , 2020, The journal of allergy and clinical immunology. In practice.

[2]  S. Fasola,et al.  Atopic dermatitis phenotypes in preschool and school-age children: a latent class analysis. , 2020, Journal of investigational allergology & clinical immunology.

[3]  W. Busse,et al.  Type 2 immunity in the skin and lungs , 2020, Allergy.

[4]  A. Licari,et al.  Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents , 2020, Pediatric Drugs.

[5]  M. Polymeropoulos,et al.  Correlation of age-of-onset of Atopic Dermatitis with Filaggrin loss-of-function variant status , 2020, Scientific Reports.

[6]  V. Shi,et al.  Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis , 2020, Journal of asthma and allergy.

[7]  M. Sugaya.  The Role of Th17-Related Cytokines in Atopic Dermatitis , 2020, International journal of molecular sciences.

[8]  D. Margolis,et al.  Identifying Phenotypes of Atopic Dermatitis in a Longitudinal US Cohort Using Unbiased Statistical Clustering. , 2020, The Journal of investigative dermatology.

[9]  S. Kežić,et al.  Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  M. D. de Bruin‐Weller,et al.  Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry , 2019, Allergy.

[11]  A. Paller,et al.  The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. , 2019, Journal of the American Academy of Dermatology.

[12]  R. Higgs,et al.  Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay , 2019, Scientific Reports.

[13]  H. Kong,et al.  Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions” , 2019, The Journal of allergy and clinical immunology.

[14]  T. Biedermann,et al.  Cutaneous Barriers and Skin Immunity: Differentiating A Connected Network. , 2018, Trends in immunology.

[15]  M. D. de Bruin‐Weller,et al.  EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients. , 2017, The Journal of allergy and clinical immunology.

[16]  T. Mustelin,et al.  Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis , 2017, The Journal of allergy and clinical immunology.

[17]  A. Dattola,et al.  The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins , 2017, Scientific Reports.

[18]  J. Krueger,et al.  Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. , 2017, The Journal of allergy and clinical immunology.

[19]  E. Guttman‐Yassky,et al.  Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers , 2017, Allergy.

[20]  J. Silverberg,et al.  Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. , 2016, Journal of the American Academy of Dermatology.

[21]  M. Suárez-Fariñas,et al.  A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. , 2016, The Journal of allergy and clinical immunology.

[22]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[23]  E. Kontny,et al.  Expression of vascular endothelial growth factor and other cytokines in atopic dermatitis, and correlation with clinical features , 2016, International journal of dermatology.

[24]  B. Thuesen,et al.  Predictive factors of self‐reported hand eczema in adult Danes: a population‐based cohort study with 5‐year follow‐up , 2016, The British journal of dermatology.

[25]  T. Biedermann,et al.  The Multi-Modal Immune Pathogenesis of Atopic Eczema. , 2015, Trends in immunology.

[26]  C. Flohr,et al.  Biomarkers for atopic dermatitis: a systematic review and meta-analysis , 2015, Current opinion in allergy and clinical immunology.

[27]  S. A. Holme,et al.  Preventing atopic eczema from birth using emollients. , 2015, The Journal of allergy and clinical immunology.

[28]  Å. Svensson,et al.  Factors that predict remission of infant atopic dermatitis: a systematic review. , 2015, Acta dermato-venereologica.

[29]  Y. Chun,et al.  Keratinocytic Vascular Endothelial Growth Factor as a Novel Biomarker for Pathological Skin Condition , 2015, Biomolecules & therapeutics.

[30]  M. Cork,et al.  Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme , 2013, BMC Dermatology.

[31]  J. Bukac,et al.  SCORAD Reflects the Duration of Atopic Dermatitis Lesions , 2013, Indian journal of dermatology.

[32]  J. Čelakovská,et al.  Allergy to Soy in an Adolescent Suffering from Atopic Dermatitis , 2013, Indian journal of dermatology.

[33]  R. Fimmers,et al.  Characterization of different courses of atopic dermatitis in adolescent and adult patients , 2013, Allergy.

[34]  E. Koczy-Baron,et al.  Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation , 2012, Inflammation Research.

[35]  Julia Oh,et al.  Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis , 2012, Genome research.

[36]  J. Ager,et al.  Changes in weather and the effects on pediatric asthma exacerbations. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[37]  N. Katoh,et al.  Prognostic factor of adult patients with atopic dermatitis , 2008, The Journal of dermatology.

[38]  P. Laudanski,et al.  Tissue inhibitors of matrix metalloproteinase‐1 levels are increased in serum of patients with allergic contact dermatitis , 2007, Contact dermatitis.

[39]  B. Niggemann,et al.  The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. , 2004, The Journal of allergy and clinical immunology.

[40]  I. Cohen,et al.  Angiogenesis-Inflammation Cross-Talk: Vascular Endothelial Growth Factor Is Secreted by Activated T Cells and Induces Th1 Polarization , 2004, The Journal of Immunology.

[41]  S. Wilhelm,et al.  Personality characteristics and serum IgE level in patients with atopic dermatitis. , 1993, Journal of psychosomatic research.

[42]  M. Klinnert,et al.  Role of behavioral health in management of pediatric atopic dermatitis. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[43]  A. Remitz,et al.  High serum total IgE predicts poor long-term outcome in atopic dermatitis. , 2015, Acta dermato-venereologica.

[44]  M. Jaakkola,et al.  Asthma and allergic rhinitis increase respiratory symptoms in cold weather among young adults. , 2014, Respiratory medicine.

[45]  K. Brew,et al.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.

[46]  J. Ring,et al.  IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. , 2009, The Journal of allergy and clinical immunology.

[47]  J. Faergemann,et al.  Prognosis and prognostic factors in adult patients with atopic dermatitis: a long‐term follow‐up questionnaire study , 2004, The British journal of dermatology.

[48]  Nitesh V. Chawla,et al.  SMOTE: Synthetic Minority Over-sampling Technique , 2002, J. Artif. Intell. Res..

[49]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.